MIMS May update

The latest in medicines news from MIMS New products Elacestrant (dihydrochloride) (Orserdu) is an orally active estrogen receptor (ER)‑α antagonist and degrader. Elacestrant inhibits the estradiol-dependent and independent growth of ERα‑positive breast cancer cells, including models harbouring estrogen receptor 1 (ESR1) gene mutations in the ligand binding domain. Elacestrant displayed antitumour activity in patient derived xenograft models